GM Joins the STAR Hunt
BETHESDA, Md-General Motors Corp. is mailing information on the opportunity for a breast cancer risk assessment, available through the Study of Tamoxifen and Raloxifene (STAR), to 140,000 of its active and retired salaried female
BETHESDA, MdGeneral Motors Corp. is mailing information on the opportunity for a breast cancer risk assessment, available through the Study of Tamoxifen and Raloxifene (STAR), to 140,000 of its active and retired salaried female employees. STAR researchers have enrolled more than 8,500 of a planned accrual of 22,000 postmenopausal women age 35 and older. The trial compares Evista (raloxifene) and Nolvadex (tamoxifen) for reducing breast cancer risk.
Articles in this issue
IOM Urges Action to Fix ‘Broken’ US Health Care System
Thompson Pledges Fundamental HCFA Reform
NCCN Updates Its Practice Guideline for Breast Cancer
Smoking Prevalence, Mortality Ranges Widely From State to State
NCI Debuts New Program for Cancer Advocates
Fiberoptic Ductoscopy for Nipple Discharge DisWomen With Nipple Discharge
Augmerosen, Antisense Drug, in Phase III Testing in Melanoma
Automated System Improves Accuracy of HER-2 Scoring
Small Advantage for Adjuvant Paclitaxel in Early Breast Cancer
New HIV Guidelines Lower the Count for Starting Therapy Antiretroviral Therapy
Prostate Cancer Research at UCSF Focuses on Dendritic Cells
Pretransplant Mylotarg Boosts Survival in Relapsed AML
Thalidomide Demonstrates Multiple Roles in Myeloma
DepoCyt, Liposomal Cytarabine, Reintroduced Into US Market
Film Mammography Still the Gold Standard: IOM Report
Recent Videos
